53 related articles for article (PubMed ID: 1887148)
1. Non-Hodgkin's lymphoma of the elderly. Prognostic factors and outcome.
Rossini F; Mingozzi S; Pogliani EM; Pioltelli P; Lanzi E; Corneo G
Recenti Prog Med; 1991 May; 82(5):262-5. PubMed ID: 1887148
[TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
3. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
5. [Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice].
van Agthoven M; Wittebol S; Budel LM; Uyl-de Groot CA; Kramer MH
Ned Tijdschr Geneeskd; 2004 Jan; 148(2):88-93. PubMed ID: 14753131
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
8. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
[TBL] [Abstract][Full Text] [Related]
9. [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
Huang HQ; Lin XB; Pan ZH; Bu Q; Gao Y; Wang BF; Cai QQ; Xia ZJ; Xu RH; Jiang WQ; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):391-5. PubMed ID: 17892140
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy].
López-Guillermo A; García-Conde J; Alvarez-Carmona AM; León P; Maldonado J; Alcalá A; Zubizarreta A; Sancho-Tello R; Carbonell F; Contreras E; Besses C; Hernando A; Fontanillas M; Montserrat E
Med Clin (Barc); 1998 May; 110(16):601-4. PubMed ID: 9656196
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
[TBL] [Abstract][Full Text] [Related]
12. [Clinical features, treatment and prognosis of 136 patients with primary non-Hodgkin's lymphoma of the nasopharynx].
Yuan ZY; Li YX; Zhao LJ; Gao YH; Liu XF; Gu DZ; Qian TN; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):425-9. PubMed ID: 15355649
[TBL] [Abstract][Full Text] [Related]
13. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma.
Daum S; Ullrich R; Heise W; Dederke B; Foss HD; Stein H; Thiel E; Zeitz M; Riecken EO
J Clin Oncol; 2003 Jul; 21(14):2740-6. PubMed ID: 12860953
[TBL] [Abstract][Full Text] [Related]
14. [The results of the combined chemoradiation treatment of lymphosarcomas corresponding to the degree of its intensity].
Kruglova GV; Finogenova IA; Shramko AF
Ter Arkh; 1991; 63(7):105-9. PubMed ID: 1788785
[TBL] [Abstract][Full Text] [Related]
15. Prognostic importance of advanced age in aggressive non-Hodgkin's malignant lymphoma.
Kovner F; Merimsky O; Inbar M; Soyfer V; Cahan Y; Rachmani R; Chaitchik S
Oncology; 1996; 53(6):435-40. PubMed ID: 8960137
[TBL] [Abstract][Full Text] [Related]
16. Hodgkin's lymphoma in the elderly: a different disease in patients over 60.
Klimm B; Diehl V; Engert A
Oncology (Williston Park); 2007 Jul; 21(8):982-90; discussion 990, 996, 998 passim. PubMed ID: 17715698
[TBL] [Abstract][Full Text] [Related]
17. The outcome of > or = 70-year-old non-Hodgkin's lymphoma patients.
Salminen EK
Int J Radiat Oncol Biol Phys; 1995 May; 32(2):349-53. PubMed ID: 7751176
[TBL] [Abstract][Full Text] [Related]
18. Non-Hodgkin's lymphoma in the older person: a review.
Ballester OF; Moscinski L; Spiers A; Balducci L
J Am Geriatr Soc; 1993 Nov; 41(11):1245-54. PubMed ID: 7693787
[TBL] [Abstract][Full Text] [Related]
19. A critical analysis of prognostic factors for survival in intermediate and high grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group Therapy Working Party.
Hayward RL; Leonard RC; Prescott RJ
Br J Cancer; 1991 Jun; 63(6):945-52. PubMed ID: 2069849
[TBL] [Abstract][Full Text] [Related]
20. Nucleolar organiser regions and survival in patients with non-Hodgkin's lymphomas classified by the working formulation.
Jakić-Razumović J; Tentor D; Petrovecki M; Radman I
J Clin Pathol; 1993 Oct; 46(10):943-7. PubMed ID: 8227414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
